Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.
Volume 31, Number 5—May 2025
Synopsis
Comprehensive Survival Analysis of Alveolar Echinococcosis Patients, University Hospital Zurich, Zurich, Switzerland, 1973–2022
Table 4
Parameters of the relative survival analysis by using an additive model for cases of alveolar echinococcosis, University Hospital Zurich, Zurich, Switzerland, 1973–2022*
Characteristic | Estimate | 95% CI | p value |
---|---|---|---|
Age at diagnosis | 0.078 | 0.05–0.11 | <0.0001 |
Year of diagnosis | −0.018 | −0.04 to 0.00 | 0.11 |
Sex, male vs. female | 0.033 | −0.47 to 0.53 | 0.90 |
Stage | −0.036 | −0.29 to 0.22 | 0.78 |
Surgery within 1 year | −0.411 | −0.93 to 0.10 | 0.12 |
Benzimidazole within 1 year | −0.514 | −1.13 to 0.10 | 0.10 |
*The additive survival model provides covariate estimates that reflect the direct effect of each covariate on the excess risk. Compared with a Cox proportional hazard, this effect is absolute and not exponential.
1These first authors contributed equally to this article.
Page created: March 11, 2025
Page updated: April 22, 2025
Page reviewed: April 22, 2025
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.